Sign in
Not yet recruitingPhase 3

Medical Nitrous Oxide Combined With Personalized Traumatic Script Exposure for the Treatment of Post-Traumatic Stress Disorder

Key facts

Who runs it
University Hospital, Tours
Where
France3 sites in 1 countryChoose a country to see its sites
Status
Not yet recruiting
Phase
Phase 3
People taking part
96 people, planned
Starts
Jan 2027
Expected to end
Jan 2031
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • MEOPA (Nitrous Oxide/Oxygen Premix)
  • Medical Air in Oxygen
  • Personalized Traumatic Script Exposure
Record updated
10 November 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Age 18 - 65
  • Patient with PTSD who has failed to respond to at least one therapeutic approach, psychotherapy or treatment with an SSRI
  • Nature of the traumatic event: interpersonal violence, including sexual, physical and psychological abuse
  • PTSD as defined by the DSM-5, with symptoms present for more than 6 months
  • CAPS-5 score ≥35
  • Participant who can receive MEOPA or medical oxygen through a face mask
  • French-speaking
  • Social security affiliation
  • Signed consent
  • A suitable method of contraception for women of childbearing age

Who cannot take part

  • Contraindication to the use of MEOPA and any condition where air is trapped inside the body and where its expansion could be dangerous: pneumothorax, emphysema, intestinal obstruction, intracranial hypertension, known and untreated deficiency of vitamin B12 or B9 (based on a test result less than 1 month old), Patients requiring ventilation with pure oxygen; any impairment of consciousness preventing patient cooperation; head injury; Gas embolism; Diving accident; Abdominal gas distension; Patient who has recently received an ophthalmic gas (SF6, C3F8, C2F6) used in eye surgery (as long as a gas bubble persists inside the eye and for a minimum period of 3 months), neurological abnormalities of recent or non-recent onset
  • Current substance use disorders or history of substance use disorder
  • Psychotic, bipolar, dissociative identity, or eating disorders; suicidal risque with C-SSR score ≥4
  • Sub-physiological plasma concentration of vitamin B12 or B9 (below the lower limit of the laboratory's reference range)
  • Supraphysiological plasma concentration of homocysteine (above the upper limit of the laboratory's reference range)
  • Pregnancy and/or breastfeeding
  • Patients subject to legal guardianship and/or other circumstances rendering the patient unable to understand the nature, purpose or consequences of the study

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this double-blind randomized controlled superiority clinical trial is to evaluate whether medical nitrous oxide/oxygen premix (MEOPA), combined with exposure to a personalized traumatic script, can improve symptoms of posttraumatic stress disorder (PTSD) in adults with treatment-resistant PTSD related to interpersonal violence.

Read full original descriptionShow less

The main questions it aims to answer are:

1. Does MEOPA combined with traumatic script exposure reduce PTSD symptom severity, as measured by the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5), compared with medical air combined with traumatic script exposure? 2. Does MEOPA improve associated symptoms and functioning, including depression, anxiety, dissociation, and functional impairment, while maintaining an acceptable safety profile?

Researchers will compare participants receiving MEOPA plus traumatic script exposure with participants receiving medical air plus traumatic script exposure to determine whether MEOPA enhances the therapeutic effects of trauma-focused re-exposure.

Participants will:

* Attend a screening and baseline assessment visit. * Complete clinician-administered and self-reported questionnaires assessing PTSD symptoms, depression, anxiety, dissociation, suicidality, and functional impairment. * Write a personalized traumatic script based on their traumatic experience. * Be randomized to receive either MEOPA or medical air. * Undergo four weekly treatment sessions consisting of inhalation of the assigned gas combined with exposure to their personalized traumatic script. * Attend follow-up visits at 1, 3, 6, and 9 months after treatment for evaluation of efficacy and safety outcomes.

The 2 groups in the trial

  • MEOPA + Personalized Traumatic Script ExposureTreatment being tested

    Participants receive inhaled medical nitrous oxide/oxygen premix (MEOPA) combined with exposure to a personalized traumatic script. Four treatment sessions are administered at weekly intervals. During each session, participants undergo 45 minutes of inhalation following the reading of their personalized traumatic script.

    Treatment: MEOPA (Nitrous Oxide/Oxygen Premix) and Personalized Traumatic Script Exposure

  • Medical Air + Personalized Traumatic Script ExposurePlacebo, for comparison

    Participants receive inhaled medical air combined with exposure to a personalized traumatic script. Four treatment sessions are administered at weekly intervals. During each session, participants undergo 45 minutes of inhalation following the reading of their personalized traumatic script.

    Treatment: Medical Air in Oxygen and Personalized Traumatic Script Exposure

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
Official title
Medical Nitrous Oxide Combined With Personalized Traumatic Script Exposure for the Treatment of Post-Traumatic Stress Disorder: A Multicenter Randomized Controlled Trial
Fit questions
Built from NCT07927192, who can take part
Record updated
10 November 2026